Recent discoveries about the effects of drugs of abuse on the brain and the mechanisms of their addictions; new chemical compounds, including immunotherapies; and new actions of available medications are offering many opportunities for the discovery and development of novel medications to treat addictive disorders. Furthermore, advancements in the understanding of the genetic and epigenetic basis of drug addiction and the pharmacogenetics of the safety and/or effi cacy of the medications are providing opportunities for more individualized pharmacotherapy approaches. Although multiple medications have been investigated for treating addictions, only a handful have shown acceptable safety and effi cacy and are approved by the US Food and Drug Administration. This article reviews the current medications that are medically safe and have shown promising results for treating opioid, cocaine, methamphetamine, and cannabis addictions.
Introduction
The development of safe, effective treatments for addictive disorders is a high public health priority because addictive disorders represent a signifi cant burden to the individual who suffers from them and to society. Addiction is a chronic condition characterized by the compulsive use of a drug in spite of the psychosocial and physical consequences of its use. It is accompanied by brain changes, which may be associated with the onset, duration, and amount of drug use. Interrupting use of the drug is often associated with craving and withdrawal symptoms, which may be alleviated by using the drug again. Its etiology is associated with genetic and environment interactions. It can be prevented and treated, and its treatment may be associated with drug use relapses.
Multiple medications have been investigated for the treatment of addictions, but only a few are approved by the US Food and Drug Administration (FDA). In recent years, various factors have facilitated progress in the development of medications to treat addictions. New research fi ndings are shedding light on the effects of drugs of abuse on the brain and are offering novel pharmacologic approaches to treat addictive disorders. Concomitantly, advances in the development of new compounds, including immunotherapies, and the discovery of new actions of available medications are allowing the evaluation of new pharmacotherapies for these disorders. In addition, the recent advancements in the understanding of the genetic and epigenetic basis of drug addiction and the pharmacogenetics of the safety and/or effi cacy of the medications used for their treatment may allow the development of more individualized pharmacotherapy approaches.
This article does not intend to be an exhaustive review of the medications that have been evaluated for treating drug addictions. Instead, the emphasis is on the novel pharmacotherapies that are more advanced in the medication development process, have shown some preliminary efficacy, and/or are being clinically evaluated for the treatment of opioid, cocaine, methamphetamine (MA), and cannabis addiction with some "promising" results. The data for this review come not only from published literature but also from open-access, Internet-based research databases such as http://www.clinicaltrials.gov (which are cited with the NCT numbers) and the Computer Retrieval of Information on Scientifi c Projects ( http://crisp.cit.nih.gov ).
Opioid Addiction
Opioid agonists such as methadone and buprenorphine and antagonists such as naloxone and naltrexone are FDA approved for treating opioid addiction. Their main indications are abstinence initiation, opioid withdrawal treatment, and relapse prevention. These medications are being investigated further to determine their safety and/or effi cacy in specifi c populations, such as pregnant women, adolescents, and people in the criminal justice system. In addition, new formulations of these medications have shown promising results and are being investigated ( Table 1 ) .
New formulations of buprenorphine intended to provide long-term delivery are being investigated to determine their safety and effi cacy for treating opioid dependence [ 1 , 2 ] . One of them, Probuphine (Titan Pharmaceuticals, South San Francisco, CA), a subcutaneous implant reported to provide 6 months of stable buprenorphine blood levels, is currently being tested in humans (NCT00630201 and NCT00447564).
Given naltrexone's opioid antagonist effects, this medication would be, in theory, an excellent option for preventing relapse among formerly opioid-dependent individuals. However, its clinical effectiveness has been disappointing because of adherence problems, given that most patients stop taking the medication early in the treatment. The recent development of sustained-release formulations of naltrexone is offering new alternatives to naltrexone that are expected to be more effective [ 3•• ]. However, not enough evidence regarding the safety and effi cacy of depot naltrexone exists to request approval from the FDA for treating opioid dependence. A study comparing oral versus depot naltrexone in a 6-month trial is being conducted to evaluate their effi cacy in maintaining opioid abstinence, medication compliance, and treatment retention (NCT00577408).
A naltrexone implant formulation with longer duration of action is also being investigated for treating opioid addiction. A study being conducted in Russia involves opioid detoxifi cation followed by treatment with oral naltrexone or a naltrexone implant manufactured and approved for use in that country. This implant is said to provide opioid blockade for 8 to 10 weeks (NCT00218426). Also, a series of studies evaluating a naltrexone implant is being conducted in Norway (NCT00204243).
α -2 adrenergic agonists such as lofexidine and clonidine have been investigated for treating opioid withdrawal but are not currently FDA approved for this indication. They may assist during the opioid detoxifi cation without the risk of opioid diversion or perpetuating opioid dependence. One of the advantages of lofexidine is that it appears to produce less hypotension than clonidine [ 4 ] . Lofexidine is currently being clinically investigated alone and in combination with naltrexone for treating opioid withdrawal in individuals undergoing opioid detoxifi cation (NCT00235729 and NCT00142909). Tramadol is a marketed analgesic with moderate μ -agonist opioid action. It may be useful for treating opioid withdrawal while producing low levels of opioid physical dependence [ 5 ] . A recent report suggests that tramadol, 200 and 400 mg, initially produced signifi cant dose-related uncomfortable effects but then suppressed opioid withdrawal. In contrast, the positive drug effects were not signifi cant, suggesting that the risk of dependence may be low [ 6 ] . Research is being conducted to determine tramadol's ability to produce opioid dependence and its effi cacy for treating opioid withdrawal (NCT00301210).
Antagonists at the N -methyl-d -aspartate (NMDA) receptor, such as memantine, ketamine, dextromethorphan, and phencyclidine, appear to prevent the development of tolerance to and dependence on the analgesic effects of morphine in rodents [ 7 ] . A recent report suggests that memantine may be moderately useful for treating opioid craving and reinforcing effects of heroin in humans, thus supporting the evidence that NMDA antagonists may be useful as an adjunct to other medications for treating opioid addiction [ 8 ] . Further research is needed to determine the role of NMDA antagonists in treating opioid addiction.
It has been reported that corticotropin-releasing hormone (CRH) antagonists can attenuate opiate withdrawal, block conditioned aversion responses, and prevent stressrelated reinstatement in preclinical models. CRH controls the hypothalamic-pituitary-adrenal axis at the basal state and in response to stress; it is also a central nervous system (CNS) modulator. Given the aversive nature of drug withdrawal syndromes, it has been suggested that CRH may be involved in the physiopathology of these syndromes. Several nonpeptidic, selective CRH-R1 receptor antagonists with clinical potential have been synthesized and are being investigated as a potential treatment for mental disorders such as anxiety and depression and for substance abuse. They may offer a therapeutic opportunity, particularly for treating opioid drug withdrawal [ 9 ] . 
